ADOPT: Lessons from comparison of glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Current Diabetes Reports

Volumn 7, Issue 3, 2007, Pages 173-174

  Yki Jarvinen, Hannele ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PROTEIN INHIBITOR; RAMIPRIL; ROSIGLITAZONE; SULFONYLUREA; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EDEMA; FRACTURE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOMES RESEARCH; QUANTITATIVE ANALYSIS; SHORT SURVEY; SIDE EFFECT; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 34250783669     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-007-0028-0     Document Type: Short Survey

References (8)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:837-852.
2. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:854-865.
3. Yki-Järvinen H: Thiazolidinediones. N Engl J Med 2004, 351:1106-1118.
4. Guan Y, Hao C, Cha DR, et al.: Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005, 11:861-866.
5. Holst JJ: Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006, 49:253-260.
6. Home PD, Pocock SJ, Beck-Nielsen H, et al.: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005, 48:1726-1735.
7. Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomized clinical trial. Lancet 2005, 366:1279-1289.
8. Mazzone T, Meyer PM, Feinstein SB, et al.: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006, 296:2572-2581.